21.50
+0.005(+0.02%)
Currency In USD
| Previous Close | 21.5 |
| Open | 21.49 |
| Day High | 21.56 |
| Day Low | 21.45 |
| 52-Week High | 23.57 |
| 52-Week Low | 6.38 |
| Volume | 3.55M |
| Average Volume | 2.99M |
| Market Cap | 2.08B |
| PE | -1,075 |
| EPS | -0.02 |
| Moving Average 50 Days | 21.15 |
| Moving Average 200 Days | 13.97 |
| Change | 21.5 |
If you invested $1000 in Avadel Pharmaceuticals plc (AVDL) 10 years ago, it would be worth $2,202.87 as of January 13, 2026 at a share price of $21.5. Whereas If you bought $1000 worth of Avadel Pharmaceuticals plc (AVDL) shares 5 years ago, it would be worth $3,204.17 as of January 13, 2026 at a share price of $21.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
GlobeNewswire Inc.
Yesterday at 9:05 PM GMT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avade
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
GlobeNewswire Inc.
Dec 18, 2025 12:00 PM GMT
- Data expected in Q2 2026 - DUBLIN, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced the completion of patient enrollment in RE
Announcement relating to despatch of Rule 15 proposal
GlobeNewswire Inc.
Dec 05, 2025 9:01 PM GMT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS IS AN ANNOUNCEMENT MADE UNDER RULE 15(C) OF